Evaluating Venture Capital Term Sheets Custom Case Solution & Analysis

1. Evidence Brief: Venture Capital Term Sheet Evaluation

Financial Metrics

Pre-money Valuation: Term Sheet A offers 10 million dollars; Term Sheet B offers 12 million dollars (Exhibit 1).
Investment Amount: Both firms propose a 5 million dollar cash infusion for Series A (Exhibit 1).
Liquidation Preference: Term Sheet A requires a 1x non-participating preferred structure. Term Sheet B demands a 2x participating preferred structure (Exhibit 2).
Option Pool: Both require a 15% post-money unallocated option pool, to be carved out of the pre-money valuation (Paragraph 14).
Anti-dilution: Term Sheet A specifies broad-based weighted average; Term Sheet B specifies full-ratchet protection (Exhibit 2).

Operational Facts

Board Composition: Term Sheet A proposes a 5-member board: 2 founders, 1 VC, 2 independents. Term Sheet B proposes a 3-member board: 1 founder, 1 VC, 1 independent (Paragraph 18).
Protective Provisions: Both term sheets include standard veto rights over asset sales, dividends, and charter amendments (Exhibit 3).
Dividends: Term Sheet A offers 8% non-cumulative dividends; Term Sheet B offers 8% cumulative dividends (Exhibit 1).

Stakeholder Positions

Founder (Sarah): Primary goal is maintaining operational control and minimizing dilution in a moderate exit scenario (Paragraph 4).
VC Firm A (Blue Chip): High-prestige firm, provides significant network access but demands lower valuation (Paragraph 9).
VC Firm B (Growth Partners): Aggressive on valuation but implements structural protections that penalize founders in sub-optimal exits (Paragraph 11).

Information Gaps

Exit Probability Distribution: The case lacks historical exit data for similar companies in the current market cycle.
Follow-on Capacity: Internal reserves of both VCs for Series B and C rounds are not explicitly stated.
Voting Thresholds: Specific percentage requirements for shareholder votes on exit events are missing.

2. Strategic Analysis

Core Strategic Question

The central dilemma is the trade-off between nominal valuation and structural downside protection. The founders must decide if a 20% higher headline valuation justifies the inclusion of a 2x participating preference and full-ratchet anti-dilution clauses.

Structural Analysis

Applying the Valuation-Control Framework reveals that Term Sheet B is a debt-like instrument disguised as equity. The 2x participating preference creates a 10 million dollar liquidation block before founders receive any proceeds. In a 20 million dollar exit, Term Sheet B investors capture 75% of the value despite owning only 29% of the equity. Term Sheet A represents a true partnership model where interests align across a broader range of exit outcomes.

Strategic Options

Accept Term Sheet A (The Alignment Path): Prioritize clean terms and investor prestige. Trade-offs: Higher immediate dilution and lower paper valuation. Resources: Requires board seat allocation and 15% option pool management.
Accept Term Sheet B (The Capital Maximization Path): Prioritize the highest headline valuation to minimize immediate dilution on paper. Trade-offs: Extreme risk in downside or moderate exit scenarios; potential for future recapitalization issues. Resources: Requires strict adherence to aggressive growth milestones to outrun the liquidation preference.
Counter-offer to Firm B: Request 1x non-participating preference in exchange for a 10 million dollar valuation. Trade-offs: Risks losing the lead investor if market sentiment is cooling.

Preliminary Recommendation

Accept Term Sheet A. The 1x non-participating preference ensures the founders are not wiped out in a moderate exit. The full-ratchet anti-dilution in Term Sheet B is toxic for future fundraising, as it creates a massive overhang that will deter Series B investors. Structure beats valuation in early-stage financing.

3. Implementation Roadmap

Critical Path

Days 1-5: Execute the 45-day exclusivity agreement with VC Firm A.
Days 6-20: Finalize the 15% employee option pool legal documentation to satisfy the pre-closing condition.
Days 21-35: Complete confirmatory due diligence, focusing on IP assignment and employment contracts.
Day 45: Close the round and appoint the first independent board member.

Key Constraints

Founder Fatigue: The negotiation process has lasted four months; Sarah’s focus has shifted from product to finance, slowing the development roadmap.
Legal Friction: Reconciling the existing cap table with the new protective provisions may require minority shareholder buy-in.

Risk-Adjusted Implementation Strategy

The primary execution risk is a delay in closing that exhausts current cash reserves. The team must maintain a bridge-loan contingency plan with existing angels. Operationally, the 15% option pool must be used immediately to hire a VP of Engineering, as the current product velocity is insufficient to meet the milestones required for a Series B. Success hinges on converting the VC's network into three enterprise pilot programs within the first 90 days post-funding.

4. Executive Review and BLUF

BLUF

Select Term Sheet A immediately. While Term Sheet B offers a 12 million dollar valuation, its 2x participating preference and full-ratchet anti-dilution create a structural trap. In any exit below 30 million dollars, the founders lose significantly more wealth under Term Sheet B than A. Furthermore, the 2-1-2 board structure in Term Sheet A provides a more stable governance environment than the 1-1-1 structure of Firm B. Clean terms are superior to high valuations for long-term enterprise viability. Sign with Firm A to secure the 5 million dollar investment and pivot focus back to product-market fit.

Dangerous Assumption

The analysis assumes the company can achieve a 50 million dollar plus exit. If the market shifts and the company must sell for 15-20 million dollars, the structural terms in Term Sheet B will effectively zero out the founder equity. The belief that valuation reflects true worth rather than a conditional loan is the most dangerous premise in the current strategy.

Unaddressed Risks

Down-round Risk: If Series B is raised at a lower valuation, the full-ratchet in Term Sheet B would cause catastrophic dilution to founders, whereas Term Sheet A’s weighted average is manageable.
Governance Gridlock: The 3-person board in Term Sheet B grants the VC an effective veto over every operational decision, creating a high probability of CEO-investor conflict.

Unconsidered Alternative

The team has not evaluated the option of a smaller 2 million dollar bridge round from existing investors to reach a higher milestone. This would allow the founders to bypass the current aggressive terms and seek a cleaner Series A in six months, though it carries significant insolvency risk if the product launch fails.